158147-30-9

Upstream product

• 288-88-0 1,2,4-Triazole 
• 158147-62-7 ethyl 2-chloromethyl-4-(3-isopropoxy-4-methoxyphenyl)-6,7-dimethoxyquinoline-3-carboxylate 
• 212490-08-9 2-(3-Isopropoxy-4-methoxy-benzyl)-3-oxo-butyric acid methyl ester 
• 212490-23-8 2-[(3,4-Dimethoxy-phenyl)-hydrazono]-3-(3-isopropoxy-4-methoxy-phenyl)-propionic acid methyl ester 
• 212490-37-4 3-(3-Isopropoxy-4-methoxy-phenyl)-5,6-dimethoxy-1H-indole-2-carboxylic acid methyl ester 
• 212489-70-8 2-amino-3'-isopropoxy-4,4',5-trimethoxybenzophenone 
• 34123-66-5 O-isopropylisovanillin 
• 638-07-3 ethyl (2-chloroaceto)acetate 

Relevant academic research and scientific papers

Studies on disease-modifying antirheumatic drugs. II. Synthesis and activity of the metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy- 2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603)

The metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2- (1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (1, TAK-603), which is under clinical evaluation as a new type of disease-modifying antirheumatic drug (DMARD), were prepared to confirm th